Oncotarget is the go to English journal for all things oncology related. It has broken a lot of useful oncology news, informing members of the public about new prevention and care treatments. Oncology is a very serious part of the medical branch as it deals with cancer, one of the leading causes of death in the world.
Oncotarget gained a following as a medical journal specifically geared towards educating everyday citizens about oncological health matters, hence the name Oncotarget. Oncotarget did not think it would grow so rapidly however. Because of its quick growth the publication was stuck with a tough decision. To make room for the new growth Oncotarget had to expand its content beyond just oncology.
Andrei V. Gudkov and Mikhail Blagosklonny were in complete agreement when it came to diversifying the journals content. Both editors in chief thought it was a great idea and committed to it fully. Their leadership, skills, and expertise made sure that it was the right choice. Oncotarget took full advantage of the change. It has been a top ranked for a number of years according to multiple reputable sources in the industry. Oncotarget is also available on Dove Press.
Oncotarget’s popularity is through the roof and steadily rising. Readers are attracted to its visionary, constructive, and comprehensive peer view approach. It is so popular it has the ability to dramatically affect the world of oncology, Neuroscience, Endocrinology, Cardiology, etc.
Each weekly issue of Oncotarget is available online on DovePress.com, a free acess site. Its primary goal isn’t to make a buck it’s to make scientific results rapidly and widely available. The best knowledge in the world is useless if only a few people are aware of it. its prominent research team continuously finds creative ways to link different fields of biomedical science. Follow Oncotarget journal on Twitter.
Oncotarget remains consistently great as other journal fluctuate.